Age, Biography and Wiki
David Lucchino was born on 16 February, 1969 in Pittsburgh, Pennsylvania, United States. Discover David Lucchino's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 54 years old?
| Popular As | N/A |
| Occupation | N/A |
| Age | 54 years old |
| Zodiac Sign | Aquarius |
| Born | 16 February, 1969 |
| Birthday | 16 February |
| Birthplace | Pittsburgh, Pennsylvania |
| Nationality | United States |
We recommend you to check the complete list of Famous People born on 16 February. He is a member of famous with the age 54 years old group.
David Lucchino Height, Weight & Measurements
At 54 years old, David Lucchino height not available right now. We will update David Lucchino's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status | |
|---|---|
| Height | Not Available |
| Weight | Not Available |
| Body Measurements | Not Available |
| Eye Color | Not Available |
| Hair Color | Not Available |
Who Is David Lucchino's Wife?
His wife is Kimberley Kissam (m. 2007) divorced 2014 Carrie-Beth (Spina) Lucchino (m. 2016)
| Family | |
|---|---|
| Parents | Frank J. Lucchino |
| Wife | Kimberley Kissam (m. 2007) divorced 2014 Carrie-Beth (Spina) Lucchino (m. 2016) |
| Sibling | Not Available |
| Children | Not Available |
David Lucchino Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is David Lucchino worth at the age of 54 years old? David Lucchino’s income source is mostly from being a successful . He is from United States. We have estimated David Lucchino's net worth , money, salary, income, and assets.
| Net Worth in 2023 | $1 Million - $5 Million |
| Salary in 2023 | Under Review |
| Net Worth in 2022 | Pending |
| Salary in 2022 | Under Review |
| House | Not Available |
| Cars | Not Available |
| Source of Income |
David Lucchino Social Network
Timeline
Lucchino began his career as a technology marketing executive working for major advertising firms in New York City. Lucchino co-founded and served as managing director of LaunchCyte, an investment firm that specializes in developing biomedical intellectual property. He led corporate development activities and secured funding for the firm’s portfolio companies. He subsequently served as a senior associate at Polaris Venture Partners, a Boston-based venture capital firm active in life sciences and technology.
Frequency is developing a form of regenerative medicine pioneered by Langer and Karp in which novel small molecules activate dormant progenitor cells within the body, enabling the restoration of function to damaged tissues. Frequency’s first therapeutic target is chronic, noise-induced hearing loss, in which the hair cells within the cochlea are damaged and die, leading to hearing loss.
Frequency’s experimental treatment, FX-322, underwent a Phase 1 first-in-human safety trial in Australia in 2017. The company announced the trial had met all endpoints.
Lucchino is active with the National Outdoor Leadership School (NOLS). He was part of a NOLS expedition that climbed Alaska’s Denali, spent 95 days living in the Rocky Mountains as part of a leadership training program, and rafted down Idaho’s “River of No Return,” the Salmon River. Lucchino was honored by NOLS as the recipient of the 2013 NOLS Alumni Service Award, “given to a devoted [NOLS] alumnus who has served the school in exemplary ways as NOLS pursues its mission to teach leadership, conservation, and outdoor skills.” He has been on the NOLS advisory council since 2014.
Lucchino has participated four times as part of the Boston Red Sox’s “Team 9” in the annual Pan-Mass Challenge, the two-day, 190-mile cycling event that raises funds for adult and pediatric cancer care and research through The Jimmy Fund at Dana-Farber Cancer Institute in Boston.
In January 2019, Lucchino announced the formation of Project Onramp, a program that matches low-income students attending four-year colleges in Massachusetts with paid internships at local biotechnology companies.
The program, formed in collaboration with MassBio, the Massachusetts Life Sciences Center, Life Science Cares and Bottom Line, is intended to give disadvantaged students their start in life science careers, which is often difficult because companies do not publicize their summer internship programs. Project Onramp was developed to help students who are not enrolled in elite schools like MIT and Harvard get a start in the life sciences industry. Industry would benefit because life sciences companies often have longstanding problems with a lack of diversity in their workforces. In May 2019, Project Onramp announced it had matched 50 Massachusetts students with internships at life sciences companies.
In August 2018, the company initiated a Phase 1/2 trial of FX-322 in the US. The trial is intended to further assess the safety of FX-322 when administered intratympanically to adult patients with stable sensoineural hearing loss and who have a medical history consistent with either noise exposure or sudden hearing loss.
In March 2018, Lucchino began a two-year term as chairman of the Massachusetts Biotechnology Council. Lucchino earlier was an elected member of the Board of Directors of the Massachusetts Biotechnology Council. He is a Trustee of Mt. Auburn Hospital, a 200-bed Harvard Medical School facility. He also serves on the Audit Committee for CareGroup: the parent organization of Mt. Auburn, Beth Israel Deaconess Medical Center and The New England Baptist Hospital.
Lucchino is the co-founder, CEO and president of Frequency Therapeutics since November 2014, first serving as chairman, and subsequently taking on the president and CEO roles alongside co-founders biomedical engineer Jeffrey Karp and Langer.
In 2013, Lucchino joined the board of the Multiple Myeloma Research Foundation.
He was a member of the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the national trade association representing the US medical device industry, from 2010 to 2013. He also serves as a director of Lipella Pharmaceuticals Inc.
Lucchino regularly appears on industry panels. He has been as a guest lecturer on entrepreneurship and innovation at colleges and universities including MIT (2007 through 2017); University of Pennsylvania Wharton School of Business (2010); Harvard Business School (2009 and 2010); Harvard Medical School (2010, 2011 and 2012); and the University of Pittsburgh (2012), where Lucchino delivered the Michael G. Wells Entrepreneurial Scholars Lecture as part of Translation Science 2012. He was selected by the Boston Business Journal as one of Boston’s “40 under Forty” leading executives, has appeared as an industry commentator on WGBH-FM (NPR) “Innovation Hub,” and is a contributor to the WBUR-FM’s “Cognoscenti” online forum , and the Boston Business Journal.
In 2006, while earning his MBA at MIT's Sloan School of Management, Lucchino was selected by MIT Institute professor, entrepreneur and inventor Dr. Robert S. Langer to team up with Dr. Christopher Loose to advance an implant surface technology that prevents blood clotting and infection. Lucchino’s team went on to win entrepreneurial competitions (by beating more than 300 teams collectively) at MIT, Harvard and Oxford universities. He continued with the team as it transformed into the company, Semprus BioSciences and Lucchino became CEO of the firm.
A Pittsburgh native, Lucchino graduated in 1987 from Central Catholic High School. He is the son of Judge Frank Lucchino and is the nephew of former Boston Red Sox president Larry Lucchino.
